ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
The Aroon Indicator for ADMA entered a downward trend on October 17, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 151 similar instances where the Aroon Indicator formed such a pattern. In of the 151 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where ADMA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on ADMA as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on November 11, 2025. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
ADMA moved above its 50-day moving average on November 11, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADMA crossed bullishly above the 50-day moving average on November 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
ADMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ADMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.803) is normal, around the industry mean (23.122). P/E Ratio (18.552) is within average values for comparable stocks, (61.014). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (8.039) is also within normal values, averaging (332.704).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| JUEZX | 27.05 | 0.17 | +0.63% |
| JPMorgan US Equity R2 | |||
| VCINX | 13.33 | N/A | N/A |
| VALIC Company I International Growth | |||
| UPMMX | 42.07 | N/A | N/A |
| Victory Precious Metals & Minerals Cl A | |||
| TNVDX | 10.74 | N/A | N/A |
| 1290 Loomis Sayles Multi-Asset Income I | |||
| ABLYX | 28.11 | -0.12 | -0.43% |
| American Beacon Large Cap Value Y | |||
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with CPRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then CPRX could also see price increases.
| Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
|---|---|---|---|---|
| ADMA | 100% | +1.75% | ||
| CPRX - ADMA | 41% Loosely correlated | +0.44% | ||
| OCUL - ADMA | 41% Loosely correlated | -1.09% | ||
| XENE - ADMA | 40% Loosely correlated | N/A | ||
| CLDX - ADMA | 39% Loosely correlated | -1.60% | ||
| VIR - ADMA | 39% Loosely correlated | +0.18% | ||
More | ||||